Cowan, Bruce A.
Olivier, Kara
Tombal, Bertrand
Wefel, Jeffrey S.
Article History
Received: 11 September 2023
Accepted: 26 October 2023
First Online: 18 November 2023
Change Date: 11 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-023-02778-6
Declarations
:
: Jeffrey S. Wefel has received financial compensation for consulting from Bayer and for research support from GT Medical Technology, Juno, Novocure. Bruce A. Cowan received financial compensation for consultancy work with Bayer. Bertrand Tombal has received financial compensation as an advisor and speaker for Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, MSD, Myovant, Novartis, and Pfizer. Kara Olivier declares that she has no competing interests.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The authors have specified in the Methods section that all participants were aware that their responses would be used to form a publication.
: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license, which permits any noncommercial use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit ExternalRef removed.